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ABSTRACT 
 
 
Title: 
The metabolic syndrome and its association with macro vascular complications of 
Diabetes Mellitus among women in an urban poor population: A cross sectional 
study. 
 
Department: 
General Medicine 
 
Name of candidate: 
Roshine Mary Koshy 
 
Degree and Subject: 
MD General Medicine Branch 1 
 
Name of guide: 
Dr O C Abraham 
  
Objectives: 
 
The study aims to assess the association between metabolic syndrome and 
macrovascular complications of diabetes mellitus among women in an urban poor 
population. 
 
  
 Methods: 
 
In this cross sectional study, newly or previously diagnosed female diabetic patients 
above the age of 30 years were recruited to the study from the out patient department 
of the Low Cost Effective Care Unit, a primary heath centre affiliated to the Christian 
Medical College and Hospital, catering to the urban poor population of Vellore city. 
All patients were screened for the metabolic syndrome according to the International 
Diabetes Federation criteria and evaluated for macrovascular complications of 
Diabetes Mellitus namely, ischemic stroke, ischemic heart disease and peripheral 
vascular disease. Data was analysed using Chi square test to determine the association 
between metabolic syndrome as a risk factor for prevalent macrovascular 
complications of Diabetes Mellitus. 
 
  
  
 
Results: 
 
75.3% of diabetic patients fulfilled the IDF criteria for the metabolic syndrome.  
The study showed a trend towards significant association between metabolic 
syndrome and macrovascular complications of diabetes mellitus with the overall 
prevalence of  macro vascular complications being 60.3 % in diabetics with the 
metabolic  syndrome and 47.4 % in those without the syndrome.( OR: 1.6, 95% CI  
:0.6 – 4.8 , p = 0.321 ) These results suggest the possibility of using the metabolic 
syndrome as a cost effective clinical tool in risk stratification in diabetics to aid in 
reducing the burden of Diabetes and its macro vascular complications in the urban 
poor population. 
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Developing countries in the Asian subcontinent have witnessed remarkable economic 
progress in the 21
st
 century. The dynamics of urbanisation has contributed 
significantly to this growth. However, it has also brought with it further disparities 
between the rich and the poor, within and between nations. 
 
India has been no stranger to this phenomenon, with the urban population contributing 
approximately 55% to the nation‟s GDP. The alarming facts are that the urban 
population in India is exploding, with estimates that India will have 41% percent of its 
population living in cities and towns by 2030 from the present level of 28%.And with 
increased urbanisation comes a steep increase in urban poverty with over 80 million 
poor people thought to be living in Indian cities and towns.(1) This phenomenon of 
urbanisation of poverty has great implications on the health of a nation. 
 
The epidemiology of diseases in developing countries like India has dramatically 
changed over the past decades with chronic diseases like Diabetes mellitus becoming 
as prevalent as infectious diseases. The International Diabetes Federation ranks India 
second with an estimated 61.3 million people living with the disease in 2011 with    
80 % of people with diabetes mellitus living in low and middle income families.(2) 
 
Observational studies in the last century highlighted that the metabolic risk factors for 
Diabetes Mellitus and cardiovascular disease overlapped significantly. This led to the 
conceptualisation of the metabolic syndrome, a syndrome of insulin resistance 
manifested clinically in the form of abdominal obesity, hyperglycemia, dyslipidemia 
and hypertension. 
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Attempts by the International Diabetes Federation to categorise the metabolic 
syndrome as a separate diagnostic entity in clinical practice was fuelled by recent 
research showing substantial evidence that the metabolic syndrome could be used as 
an independent predictor of cardiovascular mortality. 
 
Metabolic syndrome is very common in diabetics as shown by the  Third National 
Health and Nutrition Examination Survey (NHANES III) conducted in US in which 
87% of diabetics fulfilled the NCEP ATP III criteria for the metabolic syndrome. (3) 
In India, the prevalence of the metabolic syndrome among an urban diabetic 
population was found to be 87.71% in women and 69.33% in men with an overall 
prevalence of 77.2%.(4) 
 
Several studies have attempted to elucidate the association between metabolic 
syndrome in the diabetic population and macro vascular complications of diabetes. 
The Verona Diabetes Complication Study, a prospective study that aimed to analyse 
this association concluded that the presence of metabolic syndrome independently 
predicted prevalent CVD (OR 2.01, P = 0.045) and incident CVD (OR 4.89, P = 
0.031).(5) 
 
With the incidence of diabetes in India reaching epidemic proportions and 
urbanisation of poverty becoming a reality in our country widening the gap between 
the rich and the poor, the epidemiology of chronic diseases like diabetes in India 
among the urban poor is a public health issue that needs to be addressed urgently. 
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With the urban poor bearing the burden of diabetes and its dreaded complications, the 
use of the metabolic syndrome as an independent predictor of macro vascular 
complications in the diabetic population would find clinical utility in identifying 
diabetics with this syndrome so that effective treatment strategies can be instituted 
early and efficiently. This would have a great bearing on the health statistics of the 
urban poor and the country‟s economy and growth as a whole. 
 
This cross sectional study aims to evaluate the association between the metabolic 
syndrome and macrovascular complications of Diabetes Mellitus in female diabetic 
patients belonging to the urban poor population of Vellore city in Tamil Nadu. 
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DIABETES MELLITUS : MAGNITUDE AND BURDEN 
 
 
Diabetes is one of the most common non communicable disease globally and a  
challenging health issue in the 21
st
 century. 
 
The global burden of Diabetes Mellitus in the year 2011 is estimated to be 366 
million, approximately 8.3% of the world population and is expected to reach 552 
million, 9.9 % of the world‟s population by the year 2030. 
 
Epidemiological studies have shown that one in five adult diabetics live in the south 
East Asian region. (2) Research  in the epidemiology of Diabetes in the South East 
Asian population has suggested an increased predisposition for the disease in this 
population explaining the rapid increase in prevalence of diabetes in this region over 
the last two decades.(6) 
  
India stands second with an estimated 61.3 million people living with the disease in 
2011 with projected rates of 101.2 million by the year 2030.(2) 
 
Alarming health statistics from the International Diabetes Federation show that 80 % 
of people with diabetes mellitus live in low and middle income families. (2) This adds 
on to the burden of the disease in a developing country like India where the rural 
urban divide is stark. 
 
There is little systematic representative data on the prevalence of diabetes in the 
Indian population in the pre independence era. The first multi centric study conducted 
by the ICMR between 1972 and 1975 in those above 40 years of age found the 
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prevalence of diabetes mellitus to be 5% in urban and 2.8% in rural areas. The 
National Urban Diabetes Survey (NUDS) was a population based study conducted in 
2001 on subjects over 20 yrs of age which recorded the age standardised prevalence 
of type 2 diabetes to be 12.1%, with the prevalence being the highest in Hyderabad 
(16.6%), followed by Chennai (13.5%), Bengaluru (12.4%), Kolkatta (11.7%), New 
Delhi (11.6%) and Mumbai (9.3%).(7) The PODIS Study (The Prevalence Of 
Diabetes In India Study) was a  recent multistage cross-sectional population survey of 
adults in India in 2004 which recorded the standardized prevalence rates for DM in 
the total Indian population to be 4.3% with differences in prevalence rates in the  
urban and rural populations being  5.9% and 2.7% respectively.(8) 
 
The first study to be conducted in south India was a hospital based retrospective study 
in Christian College and Hospital Vellore in 1964 which showed a prevalence of 2.5% 
in hospitalised patients.(9) 
 
Subsequent population studies have shown that the prevalence varies between 0.7% in 
Pondicherry to 19.5% in Kochi in urban areas. 
 
The Chennai Urban Rural Epidemiology Study (CURES) is unique in having data 
available for comparison of prevalence rates of diabetes in Chennai with earlier 
studies using the same methodology. The CURES study, by recording a 72.3% 
increase in the prevalence of diabetes in Chennai within a 14 year time frame 
highlighted the epidemic proportion of the disease.(10) 
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THE URBAN POOR POPUALTION: 
 
 
 
URBANISATION OF POVERTY: 
 
The past century has witnessed great economic growth in the developing countries but 
has brought along with it stark disparities within developing nations. There are 
predictions of the urban population in Asia and African continents doubling in a 
period of 30 years and of an increasing rich poor divide. 
 
The urban Indian population is increasing at an alarming rate with estimates that India 
will have 41% percent of its population living in cities and towns by 2030 AD from 
the present level of 28%.(1) Urbanisation has paramount influence on the country‟s 
economy with the urban population contributing to over 55 % to the country‟s GDP. 
 
The paradox of the contribution of urbanisation to the economy lies in the fact that 
with India becoming urban, so also there is an increase in urban poverty. Latest 
survey reports suggest that there are over 80 million poor people living in the cities 
and towns of India. 
 
An interesting observation has been that the ratio of urban poverty in some of the 
larger states is higher than that of rural poverty leading to the phenomenon of 
„Urbanisation of Poverty‟.(1) 
 
Statistics in the„ India Urban Poverty report‟ which analysed health services in the 
urban population show that the wealthiest 20% of the population received about 25% 
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of the actual government health spending while the poorest 20% received only 
15%.(1) The identity of the urban poor population is created by multiple factors. Lack 
of access to formal land market force the urban poor to live in unhealthy 
environments, social discrimination increases the gap between demand and supply of 
services and financial constraints further hamper their health seeking behaviour to 
access existing health care services. 
 
Given the rapid rate of urbanisation and the significant contribution of the urban 
population to the country‟s economy, it is essential that this population is adequately 
represented in the health statistics of our country. 
 
DIABETES MELLITUS: URBAN RURAL DIFFERENCES 
 
There is consistent data regarding the urban and rural differences in the prevalence of 
diabetes in the country. 
 
Studies done in South India in the early 90‟s recorded significant urban rural 
differences in prevalence of diabetes, 8.2% in the urban and 2.4% in the rural 
population.(11) 
The National Non Communicable Diseases (NCD) Risk Factor surveillance study 
conducted between 2003 and 2005 highlighted the difference in the prevalence rates 
of diabetes in the urban, peri urban population with prevalence rates being 7.3%, 
3.2% and 3.1%.(12) The Prevalence of diabetes in India study ( PODIS) conducted in 
2004 showed a prevalence of 5.9  % and 2.7 % among urban and rural areas 
respectively as per the WHO criteria.(8) 
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THE METABOLIC SYNDROME: 
 
 
 
INTRODUCTION: 
 
The metabolic syndrome is a cluster of risk factors namely, diabetes and pre diabetes, 
abdominal obesity, high cholesterol and high blood pressure which increases the risk 
of an individual to cardiovascular disease morbidity and mortality. 
 
Though the „metabolic syndrome‟ was conceptualised over the past two decades, the 
observation that the various components of this syndrome  coexisted in a large 
proportion of patients was made almost 90 years ago.(13) 
 
The description of syndrome X or the „insulin resistance „ syndrome by G.M Reaven 
in 1988 heralded the scientific interest in this field and gave birth to the current 
evolving understanding of the „ metabolic syndrome‟.(13,14)  
 
Research in the past two decades show that insulin resistance confers on an individual 
a greater likelihood of developing glucose intolerance, specific lipid disturbances, 
essential hypertension and pro coagulant and pro inflammatory states, which in turn 
increase the risk of cardiovascular disease. The Metabolic Syndrome was created as a 
new diagnostic category to identify such persons at greater cardio vascular risk so that 
timely and appropriate management strategies could be implemented.(15) 
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PATHOGENESIS: 
 
The evolution of the concept of the „metabolic syndrome‟ came from observations 
that the metabolic risk factors for Diabetes Mellitus and cardiovascular disease 
overlapped significantly, with abdominal obesity, hyperglycaemia, dyslipidemia and 
hypertension identified as common risk factors.  
 
The results of cross sectional studies corroborated by prospective studies have shown 
that elevation of insulin concentrations precede the development of the metabolic 
syndrome. This has led to the understanding of  the underlying pathophysiology of the 
syndrome to be that of insulin resistance.(16,17)  
 
Resistance to the action of insulin leads to impaired insulin-mediated glucose uptake 
by peripheral tissues and inhibition of gluconeogenesis and lipolysis. This manifests 
clinically as glucose intolerance and dyslipidemia ( high triglycerides and low 
HDL).(18) 
  
Insulin resistance was also found to be closely related to hypertension with studies 
suggesting enhanced renal sodium retention and increased sympathetic nervous 
system activity to be key factors in both insulin resistance and hypertension.(19) 
 
Recent work on obesity leading to knowledge that the adipose tissue is an active 
endocrine organ has led to studies implicating free fatty acids and inflammatory 
mediators such as Tumour Necrosis Factor Alpha and Interleukin 6 in abnormalities 
in post receptor insulin signalling and hence the development of insulin resistance. 
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(19,20). Interesting to note was the observation that central obesity which reflected 
intra abdominal fat depots had a greater association with insulin resistance and 
cardiovascular disease than peripheral (gluteal / subcutaneous) fat depots. Though 
evidence of the pathophysiology of this phenomenon is debatable, one of the leading 
hypothesis is that intra abdominal adipocytes being lipolytically active, would 
increase intraportal FFA levels and promote insulin resistance by inhibiting insulin 
clearance by yet unidentified mechanisms.(21,22) 
 
METABOLIC SYNDROME: CRITERIA 
 
Recognising the metabolic syndrome as a diagnostic category fuelled attempts to 
formulate various criteria to be used in clinical practice.(23) 
A working definition was proposed by the World Health Organisation in 1998 which 
suggested that impaired glucose regulation or diabetes with two or more of the 
following  components constituted the metabolic syndrome: namely, raised blood 
pressure (more than or equal to 140/90 mm Hg), raised Triglycerides (more than or 
equal to 150 mg/dL) and/or low HDL ( less than 35 mg/dL in males and less than 39 
mg/dL in females), Central obesity( waist hip ratio more than 0.9 in men and more 
than 0.85 in women ) and /or BMI more than 30 mg/m2 and Microalbuminuria            
( albumin creatinine ratio of more than 30 mg/gm).(24) 
Since 1998, several other organisations have proposed other criteria, the widely used 
among them being the 2001 National Cholesterol Education Program  (NCEP) Adult 
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Treatment Panel III (ATP III) guidelines and the International Diabetes Foundation 
World Wide definition of Metabolic syndrome as described below. 
 
ATP III guidelines require the presence of three or more of the following components 
for the diagnosis of metabolic syndrome in an individual: abdominal obesity (waist 
circumference >102 cm in men and >88 cm in women), elevated blood pressure level 
(systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg), 
elevated triglycerides (≥150 mg/dl), decreased HDL cholesterol (<40 mg/dl in men 
and <50 mg/dl in women), and elevated fasting glucose (110–125 mg/dl).(25) 
 
However, the International Diabetes Federation argued that the NCEP ATP III 
guidelines were formulated primarily for research purposes and promoted the need for 
a single, universally accepted diagnostic tool that is easy to use in clinical practice as 
well as in research settings.(26) 
 
This led to the latest IDF consensus world wide definition of metabolic syndrome 
which states that for a person to be defined as having the metabolic syndrome, he/she 
must have:(27) 
 
Central obesity (defined as waist circumference ≥ 94cm for Europid men and ≥ 80cm 
for Europid women, with ethnicity specific values for other groups ; 
South Asians Based on a Chinese, Malay and Asian-Indian population; Male ≥ 90 cm 
and Female ≥ 80 cm) 
 
plus any two of the following four factors: 
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• Raised Triglyceride level: ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for this 
lipid abnormality 
 
• reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males and < 50mg/dL (1.29 
mmol/L) in females, or specific treatment for this lipid abnormality 
 
• raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or treatment 
of previously diagnosed hypertension 
 
• raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously 
diagnosed type 2 diabetes 
 
Studies comparing the impact of the use of the ATP 3 criteria and the IDF criteria in 
determining the prevalence of metabolic syndrome in populations demonstrated a 
high prevalence of the metabolic syndrome using the new IDF definition(28) 
 
 
METABOLIC SYNDROME: PREVALENCE 
 
The prevalence of this entity appears to be increasing in the West with comparison 
data from US adults of different race or ethnicity in 1988-1994 and 1999-2006 
showing significant increase from 27.9+/-1.1% to 34.1+.-0.8%.(29) The National 
Health And Nutrition Examination Survey (NHANES III) revealed startling statistics 
with approximately one fourth of adults above the age of 20 years meeting the 
diagnostic criteria for metabolic syndrome.(30) 
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What is alarming is Indian data suggesting that metabolic syndrome may be 
approaching epidemic proportions in the Asian sub continent.  
 
A population data base study of urban Asian Indian adults showed the prevalence of 
metabolic syndrome by ATP III criteria to be 41.1%.(31) 
 
The Chennai Urban Population Study-7 (CUPS-7) focussed on intra urban differences 
in the prevalence of the metabolic syndrome based on socio economic factors. The 
study which was conducted in Chennai showed an overall prevalence of the insulin 
resistance syndrome to be 11.2% with the prevalence in the middle-income group 
(18.7%) to be significantly higher compared to the low income group , 6.5%;( P < 
0.001). (32,33) 
 
METABOLIC SYNDROME IN DIABETES MELLITUS: 
Epidemiological studies in diabetes have shown that the metabolic syndrome is very 
frequently observed in diabetics. According to the NCEP study done in the US which 
analysed data of adults above the age of 50 years from the Third National Health and 
Nutrition Examination Survey (NHANES III), 87% of diabetics fulfilled the NCEP 
ATP III criteria for the metabolic syndrome.(3) In India, the prevalence of metabolic 
syndrome as per the ATP 3 criteria in an urban diabetic population in Mumbai was 
found to be 87.71% in women and 69.33% in men with an overall prevalence of 
77.2%.(4) A study done in an urban population in South India in 2005 reported the  
overall prevalence of metabolic syndrome as per the IDF criteria to be 73.3% with a 
prevalence of 83.3% in women. (34) 
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DIABETES MELLITUS: MACROVASCULAR COMPLICATIONS 
 
Chronic hyperglycemia secondary to Diabetes mellitus has been classically described 
to cause micro and macro vascular complications.  
 
Macro vascular complications which include coronary artery disease, cerebro vascular 
accidents and peripheral vascular disease share a common pathological phenomenon 
of atherosclerosis. Atherosclerosis is triggered by chronic inflammation and injury to 
the systemic arterial wall which in turn sets of a cascade of events modulated by 
inflammatory markers, macrophages and T lymphocytes eventually resulting in the 
formation of an atherosclerotic lesion which causes chronic hypoperfusion or if 
ruptured causes an acute vascular infarction .(35) 
In addition to increased likelihood of atherosclerotic plaque formation in diabetics by 
yet unknown mechanisms, increased platelet adhesion and hypercoaguability also 
contribute to the individual‟s risk of developing cardiovascular disease. 
Numerous studies have highlighted the association of cardiovascular disease and 
diabetes.  
Data from the Framingham cohort reported a twofold to threefold increase in the  risk 
of clinical atherosclerotic disease, with greatest impact on morbidity and mortality for 
intermittent claudication and congestive heart failure.(36) 
Evidence that diabetics without prior myocardial infarction have as high a risk for a 
second acute coronary event as compared to non diabetics with history of prior 
myocardial infarction (37) has prompted further research emphasizing aggressive 
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management of cardiovascular risk factors in diabetics. In fact, The American 
Diabetes Association and American Heart Association have recommended 
considering diabetes as a coronary artery disease risk equivalent rather than a risk 
factor. 
Diabetes is also a strong independent predictor of cerebro vascular disease with 
diabetes increasing ischemic stroke risk by 3% each year with the risk tripling with 
long-standing diabetes of 10 years duration. In one study, a multivariate analysis after 
adjusting for other known risk factors showed the relative risks for stroke mortality 
and morbidity associated with diabetes to be 1.8 in men and 2.2 in women. 
Epidemiological studies on the prevalence of peripheral vascular disease in diabetics 
often underestimate the true prevalence of the condition as nearly half the patients are 
asymptomatic. A pilot study using doppler to measure ankle brachial index showed a 
prevalence of 33% of asymptomatic peripheral occlusive arterial disease.(38) 
The Global Status on Non communicable Diseases Report 2011 circulated by the 
World Health Organisation reports that the year 2008 saw more than 2.5 million 
deaths from CVD in India, two-thirds due to CHD and one-third to stroke.(39) 
Epidemiological studies show clear variation in mortality trends in India with 
coronary artery disease mortality being higher in the South Indian states while stroke 
mortality is higher in the eastern states of the country.(39) 
In India, the CUPS study done in Chennai found Coronary artery disease prevalence 
rate to be 9.1% among non diabetics with prevalence rates in those diagnosed with 
diabetes to be 21.4%.(40)  
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The earliest community based epidemiological survey on stroke was conducted in 
1969-1971 in Vellore which recorded a prevalence of stroke due to any cause to be 
56.9 per 100,000.(41) There are few studies describing the trend of cerebro vascular 
diseases in South India. A study done in Kolkatta between 2003 to 2005 recorded a 
Annual Incidence Rate of 123 per 100,000 people.(42) 
Data available regarding peripheral vascular disease in diabetic in India suggest that it 
is less common among the Asian population. A cross sectional study done in South 
India recorded a prevalence of 15.4% in the diabetic population.(43) 
 
 
METABOLIC SYNDROME: A RISK FACTOR FOR MACROVASCULAR  
COMPLICATIONS IN DIABETICS 
 
Knowledge of  the primary patho physiology of the metabolic syndrome to be that of 
insulin resistance and studies suggesting that insulin resistance confers substantial 
cardiovascular risk in patients with Type 2 Diabetes mellitus has invoked interest 
among researchers in exploring the possibility of the clinical utility of the metabolic 
syndrome as a risk factor for predicting macro vascular complications in the diabetic 
population.(44) 
 
Metascreen was a multicentric diabetes clinic based survey conducted in 2002 which 
aimed to assess the degree of association and the predictive power of the metabolic 
syndrome with regard to clinically detectable complications in patients with diabetes. 
The study concluded that the metabolic syndrome , defined according to AHA or IDF 
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diagnostic criteria, was an independent clinical indicator and may be involved in the 
pathogenesis of both macro and microvascular complications of diabetes.(45) 
 
Further research in this area include data from the United Kingdom Prospective 
Diabetes Study which was analysed retrospectively to assess the impact of the 
Metabolic Syndrome on macrovascular and microvascular outcomes in patients with 
Type 2 Diabetes Mellitus. The study concluded that the metabolic syndrome 
identified diabetic patients at increased risk of future macrovascular complications 
which included sudden death, fatal or non fatal myocardial infarction and fatal or non 
fatal stroke. However, statistical analysis suggested that it lacked clinical value for 
cardiovascular Risk stratification in type 2 Diabetes mellitus.(46) 
 
The Verona Diabetes Complication study using a prospective cohort sought to analyse 
the cardiovascular risk ( fatal and non fatal coronary events, cerebro vascular 
accidents and peripheral vascular disease ) associated with the presence of the 
metabolic syndrome in patients with Type 2 Diabetes mellitus. The study concluded 
that the presence of the metabolic syndrome independently predicted prevalent CVD 
(OR 2.01, P = 0.045) and incident CVD (OR 4.89, P = 0.031).(5) 
 
Data is lacking in the Indian population as there are no studies specifically addressing 
this issue. With epidemiological trends showing an increase in the prevalence of 
diabetes and its macro vascular complications in the Indian urban poor, the use of the 
metabolic syndrome as a simple clinical tool at the primary health set up to identify  
diabetics at risk for cardiovascular disease and initiate cost effective and timely 
preventive strategies. 
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MATERIALS AND METHODS 
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An observational study of cross sectional design was conducted in the out patient 
Department of the Low Cost Effective Care Unit. 
 
The Low Cost effective Care Unit ( LCECU) is a primary level hospital affiliated to 
the Christian Medical College and Hospital providing health services to the urban 
poor population of Vellore city in the state of Tamil Nadu. It is a 48 bedded hospital 
with an out patient attendance of approximately 55,000 patients recorded the previous 
years. Around 1200 diabetic patients are seen every month in the Out Patient 
department, comprising around 33 % of the outpatient monthly statistics in the last 
one year. Weekly clinics are also conducted exclusively for diabetic patients with 
emphasis on health education regarding diabetes and its comprehensive management 
and screening of micro vascular complications. 
 
Patients were recruited into the study from the Out Patient Department of LCECU if 
they fulfilled the following criteria.  
 
Inclusion Criteria: 
1. Age more than 30 years  
2. Female gender 
3. Previously diagnosed or newly diagnosed patients with Diabetes Mellitus Type 2   
    based on a fasting capillary blood glucose more than or equal to 126 mg/dL or a 2    
    hour post prandial capillary blood more than or equal to 200 mg/dl. 
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Patients were excluded if they fulfilled any of the following criteria. 
 
Exclusion Criteria: 
1. Age less than 30 years of age 
2. Male gender 
3. Pregnant women 
4. Patients with Type 1 Diabetes Mellitus( Diagnosis made based on age of onset less   
    than 30 years of age with ketosis at presentation ) 
5. Those not consenting to be part of the study 
 
Exposure Variable: 
 
All patients included in the study were screened for the metabolic syndrome. 
A patient was said to have metabolic syndrome if she fulfilled the International  
Diabetes Federation criteria for the Metabolic syndrome ( 23 ): 
 
1. Central obesity : defined as waist circumference >/= 80 cm in females 
    Plus any two of the following two factors: 
2. Raised Triglycerides >/= 150 mg/dl or specific treatment for this lipid abnormality 
3. Reduced HDL < 50 mg/dl in females or specific treatment for this lipid abnormality 
4. Raised blood pressure ,Systolic BP >= 130 mm Hg or Diastolic BP >= 85 mm Hg   
    or treatment of previously diagnosed hypertension 
5 .Raised fasting plasma glucose > 100 mg/dl or previously diagnosed Type 2  
    Diabetes Mellitus  
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   Measurement of waist circumference : The patient is made to relax and stand   
   with her arms at the side, in a straight and upright position with feet together    
   and the waist is exposed. The  hip bone and the iliac crest  is located and the  
   measuring tape is placed  evenly around the bare abdomen at the level of the  
   iliac crest and waist circumference is measured after breathing out  normally.  
 
   Measurement of blood pressure: Blood pressure is measured from the right arm   
   after the patient has been sitting for longer than 5 min using a standard mercury  
   sphygmomanometer with cuff 13 cm wide and 42 cm long and using Korotkoffs     
   sounds I and V. Systolic and diastolic blood pressure values are recorded to the  
   nearest 2mm Hg.  
 
   An overnight  fasting plasma sample was taken from all patients and fasting   
   High Density Lipid levels and Triglyceride levels were measured. 
 
 
Outcome variable: 
 
The prevalence of the following macro vascular complications of Diabetes mellitus 
was measured in all diabetic patients included in the study. 
 
a)Ischemic stroke as evidenced by the following: 
 
1. Clinical findings as documented in medical records by a physician or elicited on   
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    examination by the principal investigator 
 
a) Cerebral cortical involvement: aphasia/neglect/motor deficit 
b) Brain stem involvement: cranial nerve deficit 
c) Cerebellar dysfunction 
 
OR 
 
2. Radiological findings 
 
a) cortical/ subcortical /cerebellar /brain stem infarct of more than 1.5 cm on CT or  
    MRI of brain ( large artery occlusion ) 
b) subcortical / brain stem infarct of less than 1.5 cm on CT or MRI of brain ( small   
    artery /lacunar infracts ) 
 
b) Ischemic Heart Disease as evidenced by the following: 
 
1) Previously diagnosed ischemic heart disease: 
 
a) Physician Documented Acute Coronary Syndrome requiring hospitalisation 
b) Exercise testing 
c) Angiography 
d) Revascularisation procedure 
  
OR 
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2) Evidence of ischemic heart disease : Defined as a positive history of Angina /   
    infarction/ angina equivalent as assessed by the London school of the modified    
    Rose Questionnaire ( 50 ) 
 
c) Peripheral vascular disease as evidenced by any one of the following, as  
    documented by a physician 
 
1. Gangrene of digits/limb OR 
 
2. History of revascularisation procedures OR 
 
3. History of Intermittent Claudication pain ( as assessed by the Edinburg  
 
    Claudication Questionairre) ( 53 )  OR 
  
4 . Ankle Brachial Index ABI ( palpatory method) < 0.9  ( 54 ) OR 
 
5. Absence of both dorsalis pedis and posterior tibial arteries on one foot or absence  
    of either of the two on both feet. 
 
The ABI was calculated as the ratio between the highest systolic blood pressure of the 
ankle and  the highest systolic blood pressure of the upper limbs as recorded by the 
palpatory method.Blood pressure measurements were taken on patients in a supine  
position, by detection of either the posterior tibial or of the dorsalis pedis artery 
during deflation of an appropriately sized cuff placed around the ankle. Pressure 
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readings were taken at reappearance of the foot pulse and approximated to two 
mmHg. Brachial blood pressures were taken by palpation of the radial pulse with 
pressure readings recorded at the reappearance of the radial pulse and approximated to  
two mmHg.  
 
                       
Bias: 
 
As gender would be a major confounder , the cross sectional study included only 
female diabetic patients. 
 
The other risk factors which might confound the outcomes, as listed below, were also 
taken into consideration during statistical analysis. 
 
1. Age 
2. Physical activity 
4. Menopausal state 
5. Family history of Diabetes Mellitus 
6. Family history of premature Heart Disease 
7. Duration and management of diabetes. 
8. Treatment for diabetes, hypertension, dyslipidemia or coronary artery disease 
 
Data including history and clinical examination was carried out by the principal  
investigator thereby minimizing inter observer bias. 
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Sample Size: 
 
A detailed scientific literature review was done to identify studies done to determine 
the prevalence of macrovascular complications in diabetic patients with the metabolic 
syndrome. 
 
The „ NCEP- Defined Metabolic Syndrome, Diabetes and Prevalence of Coronary 
Heart Disease Among NHANES III Participants Age 50 years and older ‟ study  
showed that the prevalence of metabolic syndrome in patients with Diabetes Mellitus 
was 86.5 % , the prevalence of CHD in diabetic patients with metabolic syndrome  
was 19.2%, the prevalence of CHD in diabetic patients without metabolic syndrome  
was 7.4%, with Metabolic syndrome being a significant univariate predictor  of 
prevalent CHD ( OR:2.07, 95 % CI 1.66 – 2.59)  
 
Taking the prevalence of macrovascular complications of diabetes mellitus in diabetic 
patients with metabolic syndrome to be 19% and the prevalence of macrovascular 
complications of diabetes mellitus in patients without metabolic syndrome to be 7.4%, 
with an alpha error of 0.05 and a power of 80%, the number of patients required in 
each group was calculated to be 129. 
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Statistical analysis: 
 
The prevalence of metabolic syndrome among diabetic patients was determined using 
the International Diabetes Federation criteria for metabolic syndrome and the 
prevalence of macro vascular complications of diabetes was determined in all diabetic 
patients included in the study. 
 
The Chi Square test was used to analyse risk factors  associated with metabolic syndrome and 
macro vascular complications of Diabetes Mellitus. 
 
The study protocol was presented before and approved by the Institutional Review 
Board on 6.2.2012 ( IRB Min No 7745 ). 
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RESULTS 
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The cross sectional study was carried out in the out patient clinic of the Low Cost 
Effective Care Unit from March 2012 to August 2012. A total of 106, newly or 
previously diagnosed female diabetic patients, above the age of 30 years were 
recruited into the study during this period. 29 were excluded from the final statistical 
analysis as they lacked data necessary for predictor analysis. All 106 patients were 
included in descriptive analysis while only those for whom complete data was 
available (77 patients) were included in the final statistical analysis. 
 
Descriptive Data: 
 
Given below is the descriptive analysis of the 106 diabetic patients recruited into the 
study. 
 
a) 55.7% of the diabetic patients were above the age of 50 years.  
 
b) 74.5% of patients were post menopausal. 
 
c) 47.2% of patients had history of a first degree relative diagnosed with Diabetes   
    Mellitus. 
 
d) 7.5 % of patients had history of a first degree relative who died of premature  
    coronary artery disease. 
 
e) Duration of diabetes : 16 % of patients had been diagnosed to have diabetes for    
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    more than 10 years, 50 % had the disease for a duration of 1 to 10 years while      
    31.1% of patients had been diagnosed less than a year back. Data was not available   
    for 3 patients included in the study. 
 
f) Clinical presentation at the time of diagnosis: 63.2 % of patients were diagnosed to   
    have diabetes incidentally during a health visit while 18.9% of patients presented    
    with non specific complaints. 8.5% of patients reported one of the cardinal  
    symptoms of diabetes namely polydipsia, polyphagia or polyuria to their physician   
    at presentation while 9.4% had an underlying infection detected at the time of    
    diagnosis. 
 
g) Management of diabetes: From available data, 4 patients were only on lifestyle  
    modifications, exercise and diabetic diet as part of management of diabetes. Of the  
    patients included in the study, 52.8% engaged in regular exercise which included at  
    least half an hour of brisk walking for 5 days a week. 89.6% of patients were on  
    oral anti diabetic agents while only 9.4% of patients required insulin therapy for  
    glycemic control. 
 
h) From available data, 41.5% of patients were also on some antihypertensive   
    medication,13.2% were on statins and 8.5% were on Aspirin along with    
    management of their diabetes. 
 
i) Out of the 106 diabetics enrolled in the study,80 patients (75.5%)  had a waist    
   circumference more than or equal to 80 cm. 
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j) 63 patients (59.4%) had a fasting HDL less than 50 mg/dL or were on treatment  
   with statins. 14 patients (13.2%) had the ideal HDL s above or equal to 50mg/dL.   
   Data was missing for 29 patients (27.4%) 
 
k) 34 patients (32.1%) had a fasting TGL more than or equal to 150 mg/dL or were on   
    treatment with statins.43 patients (40.6 %) had the recommended TGL level of  
    below 150 mg/dL .Data was missing for 29 patients (27.4%) 
 
l) 65 patients ( 61.3%) had a systolic BP >/= 130 mm Hg or a diastolic BP >/= 85 mm  
   Hg or were on treatment with antihypertensives. There were  42 patients  
   (39.6%) who had a systolic BP < 130 mm Hg and a diastolic BP < 85 mm Hg and  
   were not on any antihypertensives. 
 
m) Of the patients who were diagnosed to have high blood pressures or were on  
     antihypertensives, , 86.2% were on treatment with antihypertensives, 49.2% had a   
     systolic BP >/= 130 mm Hg and 18.5% had a diastolic BP >/= 85 mm Hg. 
 
n) Metabolic syndrome: 64.2% of diabetic patients included in the study fulfilled the   
    International Diabetes Federation criteria for metabolic syndrome. 27.4% of   
    patients did not satisfy the criteria while data was not available for categorisation in  
    8.5% of patients. 
 
 
    
 
 - 38 - 
 
Statistical Analysis: 
 
29 patients enrolled in the study lacked complete data that would be required for 
assessing associations as stated in the study objectives. Therefore, the predictor 
statistics, as described below, include only 77 out of the 106 patients enrolled in the 
study. 
 
1) Of the 77 patients included in the final analysis, 58 patients (75.3%) fulfilled the    
    International Diabetes Federation Criteria for the metabolic syndrome. 
 
2) Of the 58 patients who had the metabolic syndrome, all of them had a waist   
    circumference more than or equal to 80 cm, 51 patients (87.9%) fulfilled the  
    criteria of having HDL levels less than 50 mg/dl, 37 patients (63.8%) satisfied the  
    criteria of having a BP >/= 130/85 mm of Hg or were on antihypertensives and 27  
    patients (46.6%) satisfied the criteria of having TGL levels more than or equal to   
    150 mg/dl. 
     
3) Association between Metabolic syndrome and macrovacsular complications of    
    diabetes mellitus 
 
    The overall prevalence of macro vascular complications ( both ischemic heart    
    disease and peripheral vascular disease ) was 60.3 % in diabetics with the metabolic   
   
  syndrome and 47.4 % in those without the syndrome.( OR 1.69,  95% CI 0.6 – 5.0,   
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  p=0.321 ) 
 
a) Ischemic Stroke: 
 
    None of the patients included in the analysis, both those with and without the  
    metabolic  syndrome had evidence of ischemic stroke as evidenced radiologically   
    or clinically. 
 
b) Ischemic Heart Disease: 
 
    In our study, the prevalence of Ischemic heart disease was 29.3% (17) in diabetics   
    with the metabolic syndrome and 10.5 % (2) in those without the   
    syndrome ( OR 3.53, 95% CI 0.7 – 16.9 , p = 0.099 ) .  
  
    Ischemic heart disease was previously diagnosed by a physician  in only 2 patients   
    while 16 patients had a positive response to the Rose‟s questionnaire, 9 patients  
    with grade 1 angina/angina equivalent and 7 patients with grade 2 angina/angina  
    equivalent. 
 
    One of the patients who was previously diagnosed with ischemic heart disease had  
    grade 2 angina equivalent on rose‟s questionnaire. 
 
    Of the two patients with ischemic heart disease but without the metabolic   
    syndrome, both patients had Grade 1 angina equivalent on Rose‟s questionnaire.  
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c) Peripheral Vascular Disease: 
 
  In our study, in diabetics without the metabolic syndrome, the prevalence of  
  peripheral vascular disease was 36.8% (7 patients).  
 
  6 patients were diagnosed to have peripheral vascular disease based on an Ankle   
  Brachial Index less than 0.9 performed by the palpatory method. 
 
  The diagnosis of peripheral vascular disease was made in 1 patient based on a   
  positive response (Grade 2 claudication pain) on the Edinburgh claudication   
  questionnaire. However, he had a normal Ankle brachial Index of more than 0.9. 
 
  However, if the cut off for peripheral vascular index was taken to be 0.8, the   
 prevalence of PVD fell to 5.3% with diagnosis of PVD made on only one out of 19    
 diabetics without the metabolic syndrome. The patient had been diagnosed to have   
 diabetes for less than a year, had grade 2 claudication pain on the Edinburg  
 questionnaire but had an ABI>0.9. 
 
 Among the group of diabetic patients with the metabolic syndrome, 29 patients   
 (50%)  had evidence of peripheral vascular disease. 
 
 25 patients were diagnosed to have peripheral vascular disease based on an Ankle   
 Brachial Index less than 0.9 performed by the palpatory method. 
 The diagnosis of peripheral vascular disease was made in 8 patients based on a   
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  positive response to the Edinburgh claudication questionnaire with 5 patients and 3  
  patients describing Grade 1 and Grade 2 claudication pain respectively. 
 
  Of the 8 patients who were symptomatic with claudication pain, 4 of them ( 2 each   
  with grade 1 and grade 2 claudication pain) had a normal Ankle Brachial Index   
  (>0.9) 
                               
  Similarly, if the cut off for ABI was taken as 0.8, only 6 diabetic with the metabolic   
  syndrome had an ABI<0.8 bringing down the prevalence of PVD to 22.4% (13   
  patients).  
 
  Out of the 8 patients who were symptomatic with claudication pain, only one patient  
  with grade 1 claudication pain had an ABI of 0.73. 
  
  Of the 13 patients with PVD, 1 patient had been diagnosed to have diabetes for more   
  than 10 yrs, 7 had diabetes for duration of 1 to 10 years while 5 patients had been  
  diagnosed less than a year. 
 
  In summary, the prevalence of peripheral vascular disease was 50% in diabetics with  
  the  metabolic syndrome and 36.8 % in those without the syndrome. ( OR 1.71, 95%   
  CI 0.6 – 5.0 , p = 0.318)  
 
  However if the cut off for ABI was taken as less than 0.8, the prevalence of PVD in  
  diabetics with and without the metabolic syndrome was found to be 22.4% and 5.3%  
   respectively.  
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Confounders: 
 
Studies have shown that diabetic women have a greater risk of  cardiovascular disease 
when compared to men, attributed to the fact that the burden of conventional risk 
factors namely elevated blood pressure, low HDL cholesterol and high triglycerides 
are greater in diabetic women than in diabetic men (47). Gender as  a confounding 
factor was eliminated by including only female patients in the study. 
 
  As there was no association found between metabolic syndrome and macro vascular    
  complications of diabetes, analysis adjusted for confounders was not done. 
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Table 1 
 
BASELINE CHARACTERISTICS: 
 
 
 
 
 
 
Baseline characteristics 
 
 
 
Diabetics without the 
metabolic syndrome n = 19 
 
Diabetics with the metabolic 
syndrome n = 58 
Age 
 
  
> 50 years 
 
12(63.2%) 26(44.8%) 
Post menopausal state 
 
14(73.7%) 40(69%) 
Positive family history of 
Diabetes Mellitus 
 
10(52.6%) 27(46.6%) 
Positive family history of 
premature heart disease 
 
2(10.5%) 6(10.3%) 
Duration of Diabetes Mellitus 
 
  
< / =  to 1 year 
 
1 – 10 years 
 
> 10 years 
 
Data not available 
5(26.3%) 
 
11(57.9%) 
 
3(15.85) 
18(31%) 
 
29(50%) 
 
9(15.5%) 
 
2(3.4%) 
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Baseline characteristics 
 
Diabetics without the 
metabolic syndrome n = 19 
 
Diabetics with the 
metabolic syndrome n = 58 
Clinical presentation at 
diagnosis    
        
 
 
 
Incidental diagnosis 
 
Non specific symptoms 
 
Cardinal symptoms 
 
Infection         
 
14(73.7%) 
 
3(15.8%) 
 
1(5.3%) 
 
1(5.3%) 
37(63.8%) 
 
12(20.7%) 
 
4(6.9%) 
 
5(8.6%) 
Management of Diabetes  
 
  
Exercise 
 
OHA‟s 
 
Insulin 
12(63.25%) 
 
18(94.7%) 
 
4(21%) 
29(50%) 
 
50(86.2%) 
 
3(5.2%) 
Use of other medication 
 
  
Antihypertensives 
 
Statins 
 
Aspirin 
9(47.4%) 
 
1(5.3%) 
 
2(10.5%) 
 
33(56.89%) 
 
9(15.5%) 
 
5(8.6%) 
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     AGE : 
 
 
 
 
 
 
 
      N = 106 
 
 
       Figure 1: Age distribution of patients  
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MENOPAUSAL STATE: 
 
 
 
 
 
 
 
N = 106 
 
 
Figure 2: Menopausal state of diabetic women  
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FAMILY HISTORY OF DIABETES MELLITUS 
 
 
 
 
 
 
 
N = 106 
 
 
Figure 3 :Proportion of patients with history of a first degree relative diagnosed with 
diabetes mellitus 
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FAMILY HISTORY OF PREMATURE HEART DISEASE 
 
 
 
 
 
 
N = 106 
 
 
 
Figure 4: Proportion of diabetic patients with history of a first degree relative having  
 
died prematurely of an acute coronary event, less than 60 years for a male relative and  
 
less than 50 years in a female relative 
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DURATION  OF DIABETES MELLITUS: 
 
 
 
 
 
 
N = 106 
 
 
Figure 5 : Duration of diabetes  
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CLINICAL PRESENTATION AT DIAGNOSIS: 
 
 
 
 
 
 
N = 106 
 
 
Figure 6 : Clinical features with which diabetic patients presented to their physician at 
the time of diagnosis 
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MANAGEMENT OF DIABETES: 
 
 
 
 
 
 
 
N = 106 
 
 
Figure 7 : Modalities of treatment of diabetes  
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OTHER MEDICATIONS: 
 
 
 
 
 
 
 
N = 106 
 
 
Figure 8 : Other medications that diabetic patients enrolled in the study were using 
apart from medical management of diabetes 
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METABOLIC SYNDROME 
 
 
 
 
 
 
 
N = 106 
 
 
Figure 9 : Proportion of diabetic patients enrolled in the study satisfying the IDF 
criteria for the metabolic syndrome 
 
 
 
 
 
 - 54 - 
 
 
 
Diabetic Patients recruited 
 
N=106 
 
 
Patients included in Descriptive 
statistical analysis: 
 
N=106 
 
 
 
 
29 patients excluded from 
predictor statistical analysis      
( Lab Data not done ) 
 
 
 
 
 
Patients included in predictor 
statistical analysis: 
 
N=77 
 
 
 
PARTICIPANTS: 
 
 
                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             
 
 
 
 
 
 
 
 
 
Inclusion Criteria: 
 
1. Female    
    Gender 
 
2. Age > 30 
 
3.Previously or  
   Newly diagnosed   
   Diabetes Mellitus 
 - 55 - 
 
METABOLIC  SYNDROME 
 
 
 
 
 
 
 
N = 77 
 
 
Figure 10: Proportion of diabetic patients ( after exclusion of 29 patients due to lack 
of data ) who satisfied the IDF criteria for the metabolic syndrome 
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DIABETIC PATIENTS WITH METABOLIC SYNDROME: 
 
CRITERIA FULFILLED 
 
 
 
 
 
 
 
N = 58 
 
 
Figure 11: Frequency of criteria that were satisfied by  diabetic patients with the 
metabolic syndrome 
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DIABETIC PATIENTS WITH METABOLIC SYNDROME:  
 
MACROVASCULAR COMPLICATIONS 
 
 
 
 
 
 
 
N = 58 
 
 
Figure 12: Prevalence of macrovascular complications in diabetics with the metabolic 
syndrome 
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1) ISCHEMIC HEART DISEASE 
 
 
 
 
 
 
 
N = 17 
 
 
Figure 13: Criteria met by diabetic patients with the metabolic syndrome diagnosed 
with ischemic heart disease 
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2) PERIPHERAL VASCULAR DISEASE 
 
 
 
 
 
 
 
N = 29 
 
  
Figure 14 : Criteria met by diabetic patients with the metabolic syndrome diagnosed 
with peripheral vascular disease  
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B) DIABETIC PATIENTS WITHOUT METABOLIC SYNDROME:  
 
MACRO VASCULAR COMPLICATIONS 
 
 
 
 
 
 
 
N = 19 
 
 
Figure 15: Prevalence of macrovascular complications in diabetics without the 
metabolic syndrome 
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1. ISCHEMIC HEART DISEASE 
 
 
 
 
 
 
 
N = 2 
 
 
Figure 16 : Criteria met by diabetic patients without the metabolic syndrome 
diagnosed with ischemic heart disease  
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2. PERIPHERAL VASCULAR DISEASE 
 
 
 
 
 
 
 
N = 7 
 
 
Figure 17: Criteria met by diabetic patients without the metabolic syndrome 
diagnosed with peripheral vascular disease  
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METABOLIC SYNDROME AND MACROVASCULAR COMPLICATIONS 
 
 
N1 = 19 ( Diabetics without the metabolic syndrome ) 
N2 = 58 ( Diabetics with the metabolic syndrome ) 
OR : 1.69 , 95% CI : 0.6 – 4.8 
P = 0.321 
 
Figure 18: Prevalence of macrovascular complications ( Ischemic heart disease or 
peripheral vascular disease ) in diabetic patients with and without the metabolic 
syndrome 
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                                   MACROVASCULAR COMPLICATIONS 
 
                                          PRESENT                  ABSENT 
 
METABOLIC                                                                                
SYNDROME  
 
          
     PRESENT                                                                      
          
 
                                                                            
 
 
        ABSENT 
 
 
 
 
 
                                                           
                                      OR : 1.69 ,  95% CI : 0.6 – 4.8,  P = 0.321 
 
Table 2 :The prevalence of macrovascular complications ( Ischemic heart disease or 
peripheral vascular disease in diabetic patients with and without the metabolic 
syndrome 
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METABOLIC SYNDROME AND ISCHEMIC HEART DISEASE 
 
 
 
 
 
 
 
N1 = 19 ( Diabetics without the metabolic syndrome ) 
N2 = 58 ( Diabetics with the metabolic syndrome ) 
OR : 3.52 , 95% CI : 0.7 – 16.9 
P = 0.099 
 
Figure 19 : Prevalence of ischemic heart disease in diabetic patients with and without 
the metabolic syndrome 
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                                        ISCHEMIC HEART DISEASE 
 
                                          PRESENT                  ABSENT 
 
METABOLIC                                                                                
SYNDROME  
 
          
     PRESENT                                                                      
          
 
                                                                            
 
 
        ABSENT 
 
 
 
 
 
                                                           
                                      OR : 3.52 , 95% CI : 0.7 – 16.9 , P = 0.099 
 
Table 3:The prevalence of ischemic heart disease in diabetic patients with and without 
the metabolic syndrome 
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METABOLIC SYNDROME AND PERIPHERAL VASCULAR  DISEASE 
 
 
 
 
N1 = 19 ( Diabetics without the metabolic syndrome ) 
N2 = 58 ( Diabetics with the metabolic syndrome ) 
 
OR : 1.71 , 95% CI : 0.6 – 5.0 
P = 0.318 
 
 
 
Figure 20: Prevalence of peripheral vascular disease in diabetic patients with and 
without the metabolic syndrome 
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                                 PERIPHERAL VASCULAR  DISEASE 
 
                                          PRESENT                  ABSENT 
 
METABOLIC                                                                                
SYNDROME  
 
          
     PRESENT                                                                      
          
 
                                                                            
 
 
        ABSENT 
 
 
 
 
 
                                                           
                                     OR : 1.71 , 95% CI : 0.6 – 5.0, P = 0.318   
 
 
Table 4 : The prevalence of peripheral vascular disease in diabetic patients with and 
without the metabolic syndrome 
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DISCUSSION 
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    a) Metabolic syndrome in Diabetes mellitus: 
     
    Of the 77 patients included in the final analysis, 58 patients (75.3%) fulfilled the    
    International Diabetes Federation Criteria for the metabolic syndrome. This high   
    prevalence seen in diabetics is in keeping with the increased prevalence of the   
    metabolic syndrome in diabetics as studied in an urban population in South India in   
    2005 which reported an overall prevalence of metabolic syndrome as per the IDF    
    criteria to be 73.3% with a prevalence of 83.3% in women.(34) 
     
    In our study, the criteria that were fulfilled for categorising a diabetic patient to  
    have metabolic syndrome in decreasing order of prevalence was low HDL levels  
    less than 50 mg/dl (87.9%), Blood pressures >/= 130/85 mm of Hg or use of   
    antihypertensives ( 63.8%) and TGL levels more than or equal to 150 mg/dl.   
     (46.6%) 
     
    From results of the NCEP defined metabolic syndrome study done in the US,   
    low levels of HDL was the least frequent criteria that was fulfilled by diabetic  
    patients.(3) The high prevalence of diabetic patients with low levels of HDL in this  
    study corroborates with evidence suggesting that South Asians have low HDL   
   when compared to their Caucasian counterparts.(48). 
 
   In the study, only 52.8% of diabetic patients were on a regular exercise programme    
   in addition to the use of oral antidiabetic agents or insulin. Diabetic patients with the  
   metabolic syndrome should be encouraged to adhere to strict lifestyle modifications  
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   which include regular moderate intenisty 30 minute exercise and  atherogenic diet   
  along with treatment of hypertension, diabetes and dyslipidemia as per current  
  guidelines. 
 
 b) Association between Metabolic syndrome and macrovascular complications of    
    diabetes mellitus 
 
   The study showed a trend towards significant association between metabolic   
   syndrome and  macrovascular complications of diabetes mellitus with the overall   
   prevalence of  macro vascular complications ( both ischemic heart  disease and  
   peripheral vascular disease ) being 60.3 % in diabetics with the metabolic syndrome  
   and 47.4 % in those without the syndrome.( OR : 1.69, 95% CI 0.6 – 4.8,p = 0.321 ) 
 
a) Ischemic Stroke: 
 
    None of the patients included in the analysis, both those with and without the  
    metabolic syndrome had evidence of ischemic stroke as evidenced radiologically   
    or clinically. 
 
   Studies done in the West have consistently shown that the metabolic syndrome as     
   well as its individual determinants namely, hypertension, insulin resistance and  
   abnormal lipid profile are independently and significantly related to cerebro  
   vascular accidents.(49) However, the prevalence data for stroke in India is limited  
   and the earliest available statistics from South India in published literature is a  
   community based study done in Vellore which reported a crude prevalence of 57   
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   per 100,000 and an annual incidence rate of 13 per 100,000.Similar studies done  
   during the same decade show that the prevalence of stroke is lower in South Indian   
   states when compared to the North.(41,50), which could possibly explain why there    
   were no diabetic patients who were enrolled in the study with ischemic stroke. 
 
 
b) Ischemic Heart Disease: 
 
    The „ NCEP- Defined Metabolic Syndrome, Diabetes and Prevalence of Coronary    
    Heart Disease Among NHANES III Participants Age 50 years and older ‟ study  
    showed that the prevalence of CHD in diabetic patients with metabolic syndrome   
    was 19.2%, the prevalence of CHD in diabetic patients without metabolic   
    syndrome  was 7.4%.(3) CHD was diagnosed in the study based on a positive    
    Rose‟s questionnaire or a self reported acute coronary event.(51)  
 
    In our study, the prevalence of Ischemic heart disease was 29.3% (17) in diabetics   
    with the metabolic syndrome and 10.5 % in those without the metabolic syndrome     
    ( OR: 3.52, 95% CI 0.7 – 16.9,  p = 0.099 ) .  
  
    Ischemic heart disease was diagnosed in our study based on either a previously     
    documented coronary event or investigations favouring the same or a positive    
    response to a modified  Rose‟s questionnaire which included the symptomatology   
    of angina or  breathlessness on exertion and relieved by rest as an anginal   
    equivalent in a diabetic. Including breathlessnesss on exertion as an anginal  
    equivalent in the Rose‟s questionnaire is based on evidence which shows that  
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    angina pectoris is a poor indicator of myocardial ischemia in the diabetic   
    population.(52) This change in methodology could account for the increased   
    prevalence of ischemic heart disease observed in our study. 
 
    Epidemiological studies have also shown that the Asian population genotype is  
    more susceptible to coronary events , which accounts for their increased incidence  
    in this population when compared to their Caucasian counterparts. In the CUPS  
    study done in Chennai, where CAD was diagnosed based on a history of  
    documented MI or ECG changes (Minnesota codes) the prevalence of CAD among  
    diabetic patients was 21.4% when compared to those with normal glucose tolerance  
    where the prevalence was 9.1%. (40,53). 
 
 
c) Peripheral Vascular Disease: 
 
    The earliest published study looking at macro vascular complications in diabetics  
    done in South India showed that in diabetics with disease of more than 25 years, the  
    prevalence of peripheral vascular disease was 12.1% using the clinical criteria of  
    claudication pain or absent pulses and 15.4% based on Doppler studies with   
    peripheral vascular disease being diagnosed at an ABI less than 0.8.(43) 
 
   The Edinburgh claudication questionairre is a recommended epidemiological tool in    
   surveys with a sensitivity of 91.3% (95% CI 88.1–94.5%)  and a specificity of   
   99.3% (95% CI 98.9–100%).(54) 
 
 - 74 - 
  The use of the palpatory method of determining the ankle brachial index as a tool for  
  diagnosing peripheral vascular disease was studied in a primary care setting which    
  showed that the measurement of ABI by palpation in patients at intermediate    
  cardiovascular risk, was a sufficiently sensitive method for it to be to used as a    
  screening test for the exclusion of PAD.(55) 
 
  In our study, the prevalence of peripheral vascular disease was 50% in diabetics with  
  the metabolic syndrome and 36.8 % in those without the syndrome ( OR : 1.71, 95%   
  CI 0.6 – 5.0, p = 0.318 ) . 
 
  PVD  was diagnosed based on an ABI less than 0.9 in 6 out of 7 patients without the  
  metabolic syndrome and 25 out of 29 patients with the metabolic syndrome. The low  
  specificity of using the palpatory method of ABI could account for the higher  
  prevalence of PVD obtained in the study. However if the cut off for ABI was taken   
  as less than 0.8, the prevalence of PVD in diabetics with and without the metabolic    
  syndrome was found to be 22.4% and 5.3% respectively.  
 
There have been no studies in India addressing this issue and focussing on the urban 
poor population, a unique population influenced by the lifestyle changes of the cities 
and yet far behind in health awareness and access to the public heath care system in 
the cities. 
 
The cross sectional  study aimed to show a high prevalence of metabolic syndrome 
among diabetic women and a trend towards significant association between metabolic 
syndrome and macro vascular complications among female diabetic belonging to the 
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urban poor population of Vellore city. This has great implications on existing health 
services catering to the poor population in urban cities. 
 
Metabolic syndrome is becoming a public health issue of populations belonging to the 
lower socio economic strata as well. With the „ urbanisation of poverty‟, the poor 
living in Indian cities and towns are not only exposed to lifestyle changes which 
might contribute to its development, but lack of access to regular health care facilities 
delay recognition of this syndrome in diabetics and may lead to an increased 
incidence of the macro vascular complications of diabetes. This not only adds to 
mortality and morbidity but also imposes a huge economic burden on the urban poor. 
 
The diagnosis of the metabolic syndrome in diabetics would serve as a cost effective 
clinical tool in identifying diabetic patients at a risk of developing macro vascular 
complications and would aid in initiating early and appropriate management 
strategies. 
 
The treatment of metabolic syndrome in diabetics include reduction of abdominal 
obesity with diet and regular exercise, optimum glycaemic control, a goal serum LDL 
cholesterol of less than 100 mg/dL and lowering of blood pressures to less than 
130/85 mm Hg. 
 
The study was however not adequately powered curtailing its generalisability. 
Morever the population included in this study may not be truly representative of the 
urban poor population in the rest of India with respect to access to health care, health 
seeking behaviour or public awareness of health and disease. The patient population 
 - 76 - 
included in the study had good access to a primary health hospital which has a 
dedicated health education programme addressing clinical assessment and 
management of their diabetic patients on an out patient basis. The prevalence of 
macro vascular complications in diabetics with metabolic syndrome may be higher in 
other states than that estimated in this study.  
 
The strength of association between metabolic syndrome and macrovascular 
complications in diabetics as shown in this cross sectional study could pave the way 
for further prospective studies analysing the use of the metabolic syndrome as an 
independent predictor of cardio vascular risk and aid in early preventive management 
strategies in high risk individuals , thereby reducing the mortality, morbidity and 
economic burden associated with this disease in the urban population. 
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LIMITATIONS 
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1. The number of diabetics without the metabolic syndrome were considerably less  
    than those with the syndrome. Therefore, though 106 patients were enrolled into  
    the study within the given time frame , the numbers within each category was not  
    adequate to elucidate associations by statistical analysis. Hence, the results of the  
    primary objective of the study, aiming to look at association between metabolic  
    syndrome and macrovascular complications of diabetes could not be accurately  
    interpreted or extrapolated. 
 
2. As the main missing data in the study included laboratory tests for fasting HDL and  
    TGL, 29 patients lacking this data had to be excluded from the final statistical  
    analysis. 
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CONCLUSIONS 
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Of the 77 female diabetics above the age of 30 years enrolled in the study, 58 patients 
(75.3%) satisfied the IDF criteria for metabolic syndrome, namely a waist 
circumference of more than or equal to 80 cm along with one of the following three 
criteria, HDL < 50 mg/dl , TGL > 150 mg/dl or use of statins or a BP>/=130/80 mm 
Hg or use of antihypertensives. The high prevalence of the metabolic syndrome is 
consistent with published reports from South India reporting a prevalence  of 83.3% 
in women. (34) in an urban population in Chennai. 
 
The criteria met by patients in decreasing order of frequency was low HDL levels in 
87.9% of patients, BP>/=130/80  mg Hg or use of anti hypertensives in 63.8% and 
elevated TGL levels in 46.6% of patients. These results corroborate with the evidence 
that the Indian population have lower HDL‟s when compared to their Caucasian 
counterparts. 
 
The study showed a trend towards  significant association between metabolic 
syndrome and macro vascular complications of Diabetes Mellitus, namely, ischemic 
heart  disease or peripheral vascular disease. The overall prevalence of macro vascular 
complications ( both ischemic heart disease and peripheral vascular disease ) was  
60.3 % in diabetics with the metabolic syndrome and 47.4 % in those without the 
syndrome( OR : 1.69, 95% CI 0.6 – 4.8, p = 0.321 ). The prevalence of Ischemic heart 
disease was 29.3% in diabetics with the metabolic syndrome and 10.5 % in those 
without the syndrome ( OR : 3.52, 95% CI 0.7 – 16.9, p = 0.099) .The prevalence of 
peripheral vascular disease was 50% in diabetics with the metabolic syndrome and 
36.8 % in those without the syndrome ( OR: 1.71, 95% CI 0.6 – 5.0, p = 0.318 ).  
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The cross sectional study provided a glimpse into the health parameters of women 
with Type 2 diabetes mellitus ,belonging to the urban poor population of Vellore, with 
particular reference to the prevalence of the metabolic syndrome and macrovascular 
complications of diabetes in this group. 
 
The study reinforces the observation that the epidemiology of chronic diseases like 
Diabetes Mellitus in rural India is changing. The high prevalence of the metabolic 
syndrome as well as macrovascular complications of diabetes among diabetics in the 
urban rural population has great implications on the health statistics of the urban poor. 
The strength of association between metabolic syndrome and macrovascular 
complications in diabetics as shown in this study could support the clinical utility of 
the metabolic syndrome as a simple risk stratification tool in early identification and 
targeted management strategies aiding in  reducing the burden of Diabetes Mellitus 
and its macro vascular complications on the urban poor population of India. 
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PARTICIPANT   INFORMATION   SHEET 
 
 
Diabetes mellitus is a very common disease in our country and India is known to have the  
 
largest number of diabetic patients in the world. 
 
 
 
Diabetic patients need to be regularly seen by their doctor to ensure that their sugars are  
 
under control. If not , patients can have complications like ischemic heart disease,  
 
strokes, visual problems and kidney disease. 
 
 
 
There are some diabetic patients who also have hypertension, dyslipidemia or are obese.  
 
They are said to have ‘ the Metabolic syndrome’. They are more prone to develop  
 
ischemic heart disease and strokes. Hence, it is important to identify such patients so that  
 
they can be effectively treated. 
 
 
 
In this study, you will be enrolled if you have been diagnosed to have Diabetes mellitus  
 
by your doctor in LCECU. You cannot be part of the study if you are less than 30 yrs of  
 
age or are pregnant. 
 
 
 
You will examined by a doctor and will also be screened for other risk factors, namely  
 
hypertension , dyslipidemia and obesity. We will also evaluate you for evidence of  
 
ischemic heart disease or strokes in the past. We will also conduct a few routine blood  
 
tests. 
 
 
 
As part of the study, we will be screening to see if you have the metabolic syndrome and  
 
also whether you have evidence of any complications of diabetes affecting your heart or  
 
your brain. This will help you to be more aware of your illness and receive effective  
 
timely treatment. 
 
 
 
If you have any questions regarding the study, they can be conveyed to the doctor in  
 
charge at any time during the course of the study and every effort will be made to clarify  
 
your doubts. 
 
 
 
Thank you for your co operation and time. 
 
 
 
Dr Roshine Mary Koshy 
TN council 81904 
Ladies Interns Quarters 
Christian Medical college and Hospital 
Vellore 
Tamil Nadu 
 
 
Mobile no: 9442668213 
Email: roshine@gmail.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATIENT   CONSENT   FORM 
 
 
 
I have been explained in my own language  the pertinent details of the study that I will be  
 
enrolled in after my consent. I understand that I will not be exposed to any additional risk  
 
being part of this study.  
 
 
 
I understand that by being part of this study, I will be contributing to the  scientific  
 
knowledge needed to improve treatment of diabetic patients. 
 
 
 
I hereby give consent to be enrolled in the study. 
 
 
 
Signature: 
 
Name: 
 
Address: 
 
 
 
Contact no 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 Annexure IV: Patient data sheet 
 
PATIENT DATA SHEET 
 
 
Name: 
 
Age:  
 
Address: LCECU area: Yes/ No 
 
 
 
 
Occupation: 
 
 
 
History: 
 
1.Year of diagnosis of DM / age at which DM was diagnosed 
 
 
2. Clinical presentation when DM was first diagnosed: 
 
a) Asymptomatic / incidentally diagnosed 
 
b) Diabetic keto acidosis 
 
c) Infection  
 
d) ulcer/ Gangrene 
 
e) Others 
 
 
3. Macro vascular complications: 
 
a) Ischemic stroke:  
 
 
 
 1) Date of occurrence of event : 
                                  
      2) Clinical findings  -  From medical records 
 
      -  Clinical examination 
 
 a) Cerebral cortical involvement: 
      aphasia/neglect/motor deficit: 
 
 
 
b) Brain stem involvement: 
     cranial nerve deficit: 
 
 
c) Cerebellar dysfunction 
   
   
 
    3) Radiological findings: 
    
     a) Cortical/ subcortical /cerebellar /brain stem infarct of 
 
      more than 1.5 cm on  CT or MRI of brain ( large artery  
 
      occlusion ) 
 
 
 b) Subcortical / brain stem infarct of less than 1.5 cm on  
 
 CT or MRI of brain ( small artery /lacunar infarcts ) 
 
 
  4) Current neurological status/ deficits: 
 
 
 
 
b) Ischemic Heart disease: 
 
1) Previously diagnosed ischemic heart disease: Yes/No 
 
a) Physician Documented Acute Coronary Syndrome 
requiring hospitalisation: Details 
 
 
 
 
 
 
b) Exercise testing 
 
 
 
 
c) Angiography 
 
 
 
d) Revascularisation procedure 
  
 
2) Definitive evidence of ischemic heart disease:  
 
           a) Angina ( Rose Chest pain questionnaire ): Yes/ No 
 
          
 
 
c) Peripheral vascular disease: 
     
    Documented history of any of the following: 
 
         1. Gangrene of digits/limb: Yes/ No 
 
         2. History of revascularisation procedures: Yes/ No 
 
         3. History of Intermittent Claudication pain ( as assessed by the    
             Edinburg Claudication Questionairre): Yes/ No 
 
 
          4. Ankle Brachial Index by palpatory method:  
 
              Average of two reading of the highest systolic blood pressure in  
 
              upper limbs:  (nearest 2mm Hg):   
 
              Average of two reading of the highest systolic blood pressure in  
 
              lower limbs:  (nearest 2mm Hg):   
 
              Ankle brachial index:   
 
 
 
 
4. Smoking:  Currently smoking – Yes/ No 
                       
                     Past and current smoking history: 
 
                     Duration of smoking: 
 
                     Intensity ( no of cigarettes/bidis per day ) 
 
                     Pack years: 
                      Passive smoke exposure at home/work: 
 
  
 
5. Alcohol consumption: Current consumption of alcohol 
  
                                         Past and current history of alcohol consumption 
 
                                         Duration: 
 
                                         Frequency: 
 
                                         Type of alcohol: 
 
                                         Quantity: 
 
 
6. Physical activity level:  
                                       Past and current levels of physical activity : 
 
                                      Activity on job:  
 
 
 
                                      Activity in housework, child care: 
 
      
 
                                      Participation in regular exercise programme:    
                                      Specify 
 
                                  
 
7. Menarchal state:  
 
8. Family history of DM : Family tree 
 
 
 
 
 
 
 
 
8.Family history of premature heart disease: 
      
     Cardio vascular disease or sudden cardiac death in a first degree male  
 
     relative less than  55 yrs of age or a first degree female relative less  
      than 65  yrs of age: 
 
    Yes/ No 
 
 
 
9. Current treatment: 
 
a) Physical activity level: 
 
b) Anti diabetic agents/Insulin: date, compliance 
 
 
 
 
c) Other medication:  
 Antihypertensives: 
 
 
 Statins: 
 
 
 Antiplatelets: 
 
 
 Others: 
 
 
 
 
Examination: 
 
1. Weight ( kg ):    
                                      
2. Height ( cms ): 
 
3. Skin fold thickness:  
 
4. Waist circumference ( cms ): 
 
 
 
5. Blood pressure ( mm Hg ):  
Single reading if already diagnosed hypertensive. 
Average of three readings if not a known hypertensive. 
 
Reading 1: 
 
Reading 2: 
 Reading 3: 
 
6. Ankle brachial Index: 
 
 
 
Investigations 
 
1.Diagnosis of DM based on: 
     
a) Fasting plasma glucose >/= 126 mg/dL:    
Date: 
FPG: 
 
b) 2 hr post prandial plasma glucose >/= 200 mg/dL: 
Date: 
2hr PP: 
 
4. Fasting HDL 
 
5. Fasting Triglycerides 
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Appendix 3
THE LONDON SCHOOL OF HYGIENE
CHEST PAIN QUESTIONNAIRE THE
ROSE QUESTIONNAIRE'
(version for self-administration)
Part A
(a) Have you ever had any pain or discomfort
in your chest?
1. Yes
2. No
(b) Do you get this pain or discomfort when
you walk uphill or hurry?
1. Yes
2. No
(c) Do you get it when you walk at an
ordinary pace on the level?
1. Yes
2. No
(d) When you get any pain or discomfort
in your chest what do you do?
1. Stop
2. Slow down
3. Continue at the same pace
(e) Does it go away when you stand still?
1. Yes
2. No
(f) How soon?
1. 10 minutes or less
2. More than 10 minutes
(g) Where do you get this pain or discomfort?
Mark the place(s) with an X on the diagram.
Part B
Have you ever had a severe pain across the
front of your chest lasting for half an hour or more?
1. Yes
2. No
DEFINITIONS OF POSITIVE
CLASSIFICATIONS
A. Angina 'Yes' to (a) and (b),
'Stop' or 'Slow down' to (d),
'Yes' to (e),
'10 minutes or less' to (f).
Site must include either sternum (any level) or L. anterior
chest and left arm.
GRADE 1 = 'No' to (c), GRADE 2 = 'Yes' to (c).
B. Possible infarction 'Yes' in this section.
Reference
1. Rose G, McCartney P, Reid DD. Self-administration of a
questionnaire on chest pain and intermittent claudication.
Br JPrev Soc Med 1977; 31: 42-48.
Reproduced with permission of BMJ Publishing Group.
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Appendix 4
THE EDINBURGH CLAUDICATION
QUESTIONNAIRE'
(1) Do you get a pain or discomfort in your leg(s) when you
walk?
Yes
No
I am unable to walk
If you answered "Yes" to question (1) - please answer the
following questions.
Otherwise you need not continue.
(2) Does this pain ever begin when you are standing still or
sitting?
Yes
No
(3) Do you get it if you walk uphill or hurry?
Yes
No
(4) Do you get it when you walk at an ordinary pace on the
level?
Yes
No
(5) What happens to it if you stand still?
Usually continues more than 10 minutes
Usually disappears in 10 minutes or less
(6) Where do you get this pain or discomfort? Mark the
place(s) with "x" on the diagram below
Definition of positive classification requires all of the
following responses:
'Yes' to (1),
'No' to (2),
'Yes' to (3), and
'Usually disappears in 10 minutes or less' to (5);
grade 1 = 'No' to (4) and grade 2 = 'Yes' to (4).
If these criteria are fulfilled, a definite claudicant is one who
indicates pain in the calf, regardless of whether pain is also
marked in other sites; a diagnosis of atypical claudication is
made if pain is indicated in the thigh or buttock, in the
absence of any calf pain. Subjects should not be considered
to have claudication if pain is indicated in the hamstrings,
feet, shins, joints or appears to radiate, in the absence of any
pain in the calf.
Reference
1. Leng G, Fowkes F. The Edinburgh claudication
questionnaire: an improved version of the WHO/Rose
questionnaire for use in epidemiological surveys. J Clin
Epidemiol 1992; 45: 1101-1109.
Reproduced with permission of Elsevier Science, Oxford,
UK.
HOSP NO AGE DUR DIAB CF_ASYM CF_CARD CF_N SP CF_INF CF_GANG CF_DKA
170094l 45 0 0 0 1 0 0 0
310207l 50 1 0 0 1 0 0 0
073093l 65 0 1 0 0 0 0 0
209411l 40 0 0 0 1 0 0 0
051494l 50 0 0 0 1 0 0 0
078907l 43 1 0 0 1 0 0 0
219011l 37 0 0 0 0 1 0 0
097512l 47 0 0 0 1 0 0 0
327505l 40 1 0 0 1 0 0 0
136804l 49 1 1 0 0 0 0 0
222603l 54 1 0 0 1 0 0 0
338799l 54 2 0 0 0 1 0 0
299705l 45 0 1 0 0 0 0 0
271101l 50 0 1 0 0 0 0 0
068111l 45 0 0 0 1 0 0 0
143111l 60 0 1 0 0 0 0 0
076411l 48 0 1 0 0 0 0 0
318699l 51 1 1 0 0 0 0 0
302608l 58 99 1 0 0 0 0 0
275649s 70 99 1 0 0 0 0 0
197994l 67 99 1 0 0 0 0 0
393201l 45 1 1 0 0 0 0 0
268108l 35 1 1 0 0 0 0 0
234210l 47 1 0 1 0 0 0 0
340347s 47 1 1 0 0 0 0 0
HOSP NO AGE DUR DIAB CF_ASYM CF_CARD CF_N SP CF_INF CF_GANG CF_DKA
170809l 60 1 0 0 1 0 0 0
119108l 47 1 0 0 1 0 0 0
072488l 50 1 1 0 0 0 0 0
168855s 60 1 0 0 0 1 0 0
081511l 42 0 1 0 0 0 0 0
123095l 65 1 1 0 0 0 0 0
059195l 60 2 1 0 0 0 0 0
230100l 80 1 1 0 0 0 0 0
094112l 60 0 1 0 0 0 0 0
129908l 65 1 1 0 0 0 0 0
230904l 60 1 0 0 0 1 0 0
037703l 60 2 0 0 0 0 0 0
110404l 50 1 1 0 0 0 0 0
074607l 65 1 1 0 0 0 0 0
176125s 70 1 0 1 0 0 0 0
340689s 65 1 1 0 0 0 0 0
087904l 65 2 0 1 0 0 0 0
097008l 40 1 1 0 0 0 0 0
034112l 41 1 1 0 0 0 0 0
175207l 60 1 1 0 0 0 0 0
157706l 55 1 1 0 0 0 0 0
295201l 60 0 1 0 0 0 0 0
238503l 60 1 1 0 0 0 0 0
055210l 65 1 1 0 0 0 0 0
HOSP NO AGE DUR DIAB CF_ASYM CF_CARD CF_N SP CF_INF CF_GANG CF_DKA
091309l 60 1 1 0 0 0 0 0
222974s 50 1 1 0 0 0 0 0
9999999 50 2 0 0 0 1 0 0
159689l 60 1 1 0 0 0 0 0
083412l 60 0 1 0 0 0 0 0
289602l 60 2 1 0 0 0 0 0
159705l 60 2 1 0 0 0 0 0
313004l 60 1 1 0 0 0 0 0
243511l 60 2 0 1 0 0 0 0
217008l 48 0 1 0 0 0 0 0
080607l 70 1 1 0 0 0 0 0
467306l 50 2 0 1 0 0 0 0
034912l 50 0 1 0 0 0 0 0
050511l 61 2 1 0 0 0 0 0
313506l 46 1 0 1 0 0 0 0
106911l 60 0 0 0 0 1 0 0
157607l 45 1 1 0 0 0 0 0
256004l 35 0 0 0 0 1 0 0
142810l 40 0 0 1 0 0 0 0
097712l 50 0 1 0 0 0 0 0
125204l 65 1 1 0 0 0 0 0
216501l 60 0 1 0 0 0 0 0
102104l 42 0 0 0 1 0 0 0
186694l 60 0 0 0 1 0 0 0
201689l 60 1 1 0 1 0 0 0
HOSP NO AGE DUR DIAB CF_ASYM CF_CARD CF_N SP CF_INF CF_GANG CF_DKA
045195l 55 1 0 0 1 0 0 0
476201l 48 0 1 0 0 0 0 0
013003l 38 1 1 0 0 0 0 0
209005l 56 0 0 0 1 0 0 0
098697l 55 1 0 0 0 1 0 0
329906l 62 2 1 0 0 0 0 0
089604l 40 1 1 0 0 0 0 0
341799l 46 1 1 0 0 0 0 0
155506l 50 0 1 0 0 0 0 0
117205l 75 2 1 0 0 0 0 0
068600l 70 1 0 1 0 0 0 0
070900l 65 1 1 0 0 0 0 0
100412l 35 0 1 0 0 0 0 0
422105l 59 1 1 0 0 0 0 0
026202l 65 2 0 0 0 1 0 0
084204l 40 0 1 0 0 0 0 0
242711l 38 0 0 0 1 0 0 0
123006l 36 0 0 0 1 0 0 0
060111l 65 1 1 0 0 0 0 0
319507l 57 0 1 0 0 0 0 0
121907l 62 1 1 0 0 0 0 0
132308l 60 1 1 0 0 0 0 0
188710l 60 1 1 0 0 0 0 0
1702/97a 63 1 1 0 0 0 0 0
HOSP NO AGE DUR DIAB CF_ASYM CF_CARD CF_N SP CF_INF CF_GANG CF_DKA
024305l 70 1 1 0 0 0 0
323399l 45 2 1 0 0 0 0 0
187802l 71 2 0 0 1 0 0 0
365406l 60 2 1 0 0 0 0 0
HOSP NO IS_CF IS_RF IHD_PD IHD_R1 IHD_R2 PVD_G PVD_RV PVD_IC1
170094l 0 0 0 0 0 0 0 0
310207l 0 0 0 0 0 0 0 0
073093l 0 0 0 0 1 0 0 0
209411l 0 0 0 1 0 0 0 0
051494l 0 0 0 0 0 0 0 0
078907l 0 0 0 1 0 0 0 0
219011l 0 0 0 0 0 0 0 0
097512l 0 0 0 0 0 0 0 0
327505l 0 0 0 0 0 0 0 0
136804l 0 0 1 0 1 0 0 0
222603l 0 0 0 1 0 0 0 0
338799l 0 0 0 0 0 0 0 0
299705l 0 0 0 0 0 0 0 0
271101l 0 0 0 0 0 0 0 0
068111l 0 0 0 0 0 0 0 0
143111l 0 0 0 0 0 0 0 0
076411l 0 0 0 0 0 0 0 0
318699l 0 0 0 0 1 0 0 1
302608l 0 0 0 0 0 0 0 0
275649s 0 0 0 0 0 0 0 0
197994l 0 0 0 0 0 0 0 0
393201l 0 0 0 0 0 0 0 0
268108l 0 0 0 0 0 0 0 0
234210l 0 0 0 1 0 0 0 0
340347s 0 0 0 0 0 0 0 0
HOSP NO IS_CF IS_RF IHD_PD IHD_R1 IHD_R2 PVD_G PVD_RV PVD_IC1
170809l 0 0 0 0 0 0 0 0
119108l 0 0 0 1 0 0 0 1
072488l 0 0 0 0 0 0 0 0
168855s 0 0 0 0 0 0 0 0
081511l 0 0 0 1 0 0 0 0
123095l 0 0 0 0 0 0 0 0
059195l 0 0 0 0 0 0 0 0
230100l 0 0 0 0 0 0 0 0
094112l 0 0 0 1 0 0 0 0
129908l 0 0 0 0 0 0 0 0
230904l 0 0 0 0 0 0 0 0
037703l 0 0 0 0 0 0 0 0
110404l 0 0 0 1 0 0 0 0
074607l 0 0 0 0 0 0 0 0
176125s 0 0 0 0 0 0 0 0
340689s 0 0 0 0 0 0 0 0
087904l 0 0 0 0 0 0 0 0
097008l 0 0 0 0 0 0 0 0
034112l 0 0 0 0 0 0 0 0
175207l 0 0 0 1 0 0 0 0
157706l 0 0 0 0 0 0 0 0
295201l 0 0 0 1 0 0 0 0
238503l 0 0 0 1 0 0 0 0
055210l 0 0 0 0 0 0 0 0
HOSP NO IS_CF IS_RF IHD_PD IHD_R1 IHD_R2 PVD_G PVD_RV PVD_IC1
091309l 0 0 0 0 0 0 0 0
222974s 0 0 0 0 0 0 0 0
9999999 0 0 0 1 0 0 0 0
159689l 0 0 0 1 0 0 0 1
083412l 0 0 0 0 0 0 0 0
289602l 0 0 0 0 0 0 0 0
159705l 0 0 0 0 0 0 0 0
313004l 0 0 0 0 0 0 0 0
243511l 0 0 0 0 1 0 0 0
217008l 0 0 0 0 1 0 0 0
080607l 0 0 0 0 0 0 0 1
467306l 0 0 0 1 0 0 0 0
034912l 0 0 0 0 0 0 0 0
050511l 0 0 0 0 0 0 0 0
313506l 0 0 0 0 0 0 0 0
106911l 0 0 0 0 0 0 0 0
157607l 0 0 0 0 0 0 0 0
256004l 0 0 0 0 0 0 0 0
142810l 0 0 0 0 0 0 0 0
097712l 0 0 0 0 0 0 0 0
125204l 0 0 0 0 1 0 0 0
216501l 0 0 0 0 0 0 0 0
102104l 0 0 0 0 0 0 0 0
186694l 0 0 0 0 0 0 0 0
201689l 0 0 0 0 1 0 0 1
HOSP NO IS_CF IS_RF IHD_PD IHD_R1 IHD_R2 PVD_G PVD_RV PVD_IC1
045195l 0 0 1 0 0 0 0 0
476201l 0 0 0 0 0 0 0 0
013003l 0 0 0 0 0 0 0 0
209005l 0 0 0 0 0 0 0 0
098697l 0 0 0 0 0 0 0 0
329906l 0 0 1 0 0 0 0 0
089604l 0 0 0 0 0 0 0 0
341799l 0 0 0 0 0 0 0 0
155506l 0 0 0 0 0 0 0 0
117205l 0 0 0 0 0 0 0 0
068600l 0 0 0 1 0 0 0 0
070900l 0 0 0 0 0 0 0 0
100412l 0 0 0 0 0 0 0 0
422105l 0 0 0 1 0 0 0 0
026202l 0 0 0 0 0 0 0 0
084204l 0 0 0 0 0 0 0 0
242711l 0 0 0 0 0 0 0 0
123006l 0 0 0 0 0 0 0 0
060111l 0 0 0 0 0 0 0 0
319507l 0 0 0 0 0 0 0 0
121907l 0 0 0 0 0 0 0 0
132308l 0 0 0 1 0 0 0 0
188710l 0 0 0 0 1 0 0 0
1702/97a 0 0 0 0 0 0 0 0
HOSP NO IS_CF IS_RF IHD_PD IHD_R1 IHD_R2 PVD_G PVD_RV PVD_IC1
024305l 0 0 0 0 1 0 0 0
323399l 0 0 0 0 1 0 0 0
187802l 0 0 0 0 1 0 0 0
365406l 0 0 0 0 0 0 0 0
HOSP NO PVD_IC2 PVD_ABI PA_E POST MP FAM_DM FAM_IHD T_INS T_OHA
170094l 0 0 0 0 1 0 0 1
310207l 0 1 1 1 0 0 0 1
073093l 0 1 0 1 0 0 0 1
209411l 0 1 0 1 0 0 0 1
051494l 0 0 1 0 1 1 9 9
078907l 0 1 0 0 1 0 0 1
219011l 0 0 1 0 1 0 0 1
097512l 0 0 1 0 0 0 0 1
327505l 0 0 1 0 1 1 0 1
136804l 0 0 0 0 0 0 0 1
222603l 1 1 0 1 1 1 0 1
338799l 0 1 0 1 0 0 1 1
299705l 0 1 0 1 1 0 0 1
271101l 0 1 0 1 1 0 0 0
068111l 0 0 1 1 0 0 0 1
143111l 0 0 0 1 0 0 0 0
076411l 0 1 1 1 0 0 0 1
318699l 0 0 1 1 1 0 0 1
302608l 0 0 1 1 0 0 0 1
275649s 0 0 0 1 0 0 0 1
197994l 0 0 1 1 1 0 0 1
393201l 0 1 1 0 0 0 0 0
268108l 0 1 1 0 1 1 0 1
234210l 1 1 0 0 0 0 9 9
340347s 0 1 1 0 1 0 1 1
HOSP NO PVD_IC2 PVD_ABI PA_E POST MP FAM_DM FAM_IHD T_INS T_OHA
170809l 0 0 0 1 0 0 0 1
119108l 0 0 1 1 0 0 0 1
072488l 0 0 1 1 1 0 0 1
168855s 0 0 1 1 0 0 0 1
081511l 0 0 0 0 1 0 0 0
123095l 0 0 1 1 0 0 0 1
059195l 0 0 1 1 0 0 1 1
230100l 0 1 0 1 0 0 0 1
094112l 0 0 1 1 0 0 0 1
129908l 0 0 0 1 0 0 0 1
230904l 0 0 1 1 1 0 0 1
037703l 0 1 0 1 0 0 0 1
110404l 0 0 1 0 0 0 0 1
074607l 0 0 0 1 0 0 0 1
176125s 0 1 0 1 0 0 1 1
340689s 0 0 1 1 1 0 0 1
087904l 0 0 0 1 1 0 1 1
097008l 0 1 1 1 1 0 0 1
034112l 0 0 0 0 1 0 0 1
175207l 1 0 0 1 0 0 0 1
157706l 0 0 1 1 0 0 0 1
295201l 0 1 1 1 0 0 0 1
238503l 0 0 0 1 0 0 0 1
055210l 0 0 0 1 0 0 9 9
HOSP NO PVD_IC2 PVD_ABI PA_E POST MP FAM_DM FAM_IHD T_INS T_OHA
091309l 0 0 1 1 0 0 1 1
222974s 0 1 0 1 1 0 0 1
9999999 1 1 0 1 1 0 1 1
159689l 0 1 1 1 1 0 9 9
083412l 0 1 1 1 1 0 0 1
289602l 0 0 0 1 1 1 0 1
159705l 0 0 0 1 0 0 0 1
313004l 0 0 0 1 1 0 0 1
243511l 0 0 0 1 1 1 0 1
217008l 1 1 0 1 1 0 0 1
080607l 0 1 0 1 0 0 0 1
467306l 0 1 0 0 0 0 0 1
034912l 0 1 0 1 0 0 0 1
050511l 0 1 0 1 0 0 0 1
313506l 0 0 0 0 1 0 0 1
106911l 0 0 1 1 0 0 0 1
157607l 0 1 9 0 0 0 9 9
256004l 0 1 1 0 0 0 9 9
142810l 0 0 1 0 0 0 0 1
097712l 0 1 0 1 1 0 0 1
125204l 0 0 1 1 1 1 0 1
216501l 0 1 1 1 1 0 0 1
102104l 0 0 1 0 0 0 0 1
186694l 1 0 0 1 1 0 0 1
201689l 0 0 1 1 0 0 0 1
HOSP NO PVD_IC2 PVD_ABI PA_E POST MP FAM_DM FAM_IHD T_INS T_OHA
045195l 0 0 1 1 0 0 0 1
476201l 0 0 1 0 0 0 0 1
013003l 0 0 1 0 1 0 0 1
209005l 0 0 0 1 1 0 0 1
098697l 0 1 1 1 1 0 0 1
329906l 0 1 1 1 1 0 0 1
089604l 0 1 1 0 0 0 0 1
341799l 0 0 1 1 1 0 0 1
155506l 0 0 0 1 0 0 0 1
117205l 0 0 0 1 1 0 0 1
068600l 0 0 0 1 1 0 1 1
070900l 0 0 0 1 1 0 0 1
100412l 0 1 0 0 0 0 0 0
422105l 0 0 1 1 0 0 0 1
026202l 0 0 1 1 1 0 0 1
084204l 0 0 1 0 0 0 0 1
242711l 0 0 1 0 1 1 0 1
123006l 0 0 0 0 0 0 0 1
060111l 0 1 0 1 0 0 0 1
319507l 0 0 1 1 0 0 0 1
121907l 0 0 1 1 1 0 0 1
132308l 0 0 1 1 1 0 0 1
188710l 1 1 0 1 1 0 1 1
1702/97a 0 0 1 1 1 0 0 1
HOSP NO PVD_IC2 PVD_ABI PA_E POST MP FAM_DM FAM_IHD T_INS T_OHA
024305l 1 1 0 1 1 0 0 1
323399l 1 0 1 1 0 0 0 1
187802l 0 1 0 1 0 0 0 1
365406l 0 0 1 1 1 0 0 1
HOSP NO T_HTNA T_HTNB T_HTNC T_HTND T_STAT T_ASP WEIGHT HEIGHT
170094l 1 0 0 0 0 0 61 155
310207l 0 0 1 0 0 0 53 149
073093l 1 1 0 1 1 0 94 150
209411l 1 0 0 0 0 0 59 148
051494l 9 9 9 9 9 9 66 150
078907l 0 1 0 0 0 0 60 139
219011l 0 0 0 0 0 0 46 148
097512l 0 0 0 0 0 0 74 149
327505l 0 0 0 0 0 0 40 152
136804l 1 0 0 0 1 1 61 145
222603l 1 0 0 1 0 0 60 137
338799l 1 0 0 1 0 1 58 147
299705l 1 1 0 1 1 0 79 151
271101l 0 0 0 1 0 0 80 157
068111l 0 0 0 0 0 0 66 158
143111l 0 0 0 0 0 0 56 146
076411l 0 0 0 0 0 0 64 153
318699l 0 1 1 0 1 0 70 156
302608l 1 0 1 0 0 0 66 155
275649s 0 0 0 0 0 0 57 143
197994l 1 0 1 0 0 0 58 154
393201l 0 0 0 0 0 0 61 157
268108l 1 0 0 0 0 0 66 151
234210l 9 9 9 9 9 9 87 156
340347s 1 0 0 0 0 0 48 154
HOSP NO T_HTNA T_HTNB T_HTNC T_HTND T_STAT T_ASP WEIGHT HEIGHT
170809l 0 0 1 0 0 0 59 147
119108l 0 0 1 0 0 0 55 148
072488l 1 0 0 0 0 0 51 149
168855s 0 0 0 0 0 0 58 154
081511l 0 0 0 0 0 0 72 156
123095l 1 0 1 0 0 0 55 153
059195l 0 0 0 0 0 0 31 136
230100l 0 0 0 0 0 0 46 142
094112l 0 0 0 0 0 0 50 152
129908l 0 0 0 0 0 0 51 149
230904l 0 0 0 0 0 0 53 146
037703l 1 0 0 0 0 0 74 150
110404l 1 0 0 0 0 0 67 150
074607l 1 0 0 0 0 0 40 134
176125s 1 0 0 0 0 0 36 143
340689s 1 0 0 0 0 0 39 144
087904l 1 0 0 0 1 1 45 144
097008l 1 0 0 0 0 0 75 153
034112l 0 0 0 0 0 0 65 152
175207l 1 0 0 0 0 0 48 144
157706l 1 0 0 0 0 0 47 144
295201l 1 0 0 0 0 0 63 150
238503l 1 1 0 0 0 0 66 155
055210l 9 9 9 9 9 9 61 159
HOSP NO T_HTNA T_HTNB T_HTNC T_HTND T_STAT T_ASP WEIGHT HEIGHT
091309l 1 0 0 0 0 0 46 144
222974s 0 0 0 0 0 0 56 146
9999999 0 0 0 0 0 0 58 153
159689l 9 9 9 9 9 9 62 153
083412l 0 0 0 0 0 0 65 151
289602l 0 0 0 0 0 0 44 149
159705l 1 0 0 0 0 0 74 153
313004l 0 0 0 0 0 0 54 153
243511l 1 0 0 0 1 0 59 146
217008l 1 0 0 0 0 0 73 156
080607l 0 0 0 0 1 0 49 152
467306l 1 0 1 0 0 0 68 146
034912l 1 0 0 0 0 0 60 145
050511l 1 1 0 0 0 0 44 147
313506l 0 0 0 0 0 0 72 155
106911l 0 0 0 0 0 0 45 149
157607l 9 9 9 9 9 9 73 157
256004l 9 9 9 9 9 9 69 148
142810l 0 0 0 0 0 0 85 160
097712l 0 0 0 0 0 0 41 149
125204l 1 0 0 0 0 1 56 154
216501l 1 0 1 0 0 0 44 157
102104l 0 1 0 1 0 0 54 151
186694l 0 0 0 0 1 1 50 150
201689l 0 1 0 1 1 0 62 150
HOSP NO T_HTNA T_HTNB T_HTNC T_HTND T_STAT T_ASP WEIGHT HEIGHT
045195l 1 0 0 0 0 0 63 158
476201l 0 0 0 1 0 0 58 148
013003l 0 0 0 0 0 0 79 147
209005l 0 0 0 0 1 0 74 163
098697l 1 0 0 0 0 0 70 154
329906l 0 0 0 0 0 0 59 150
089604l 0 0 0 0 0 0 59 157
341799l 0 0 0 0 0 0 50 152
155506l 0 0 0 0 1 0 51 143
117205l 1 1 0 0 0 0 57 149
068600l 0 1 0 0 0 0 44 145
070900l 0 0 0 0 0 0 60 153
100412l 0 0 0 0 0 0 57 156
422105l 0 0 0 0 0 0 49 145
026202l 1 0 1 0 0 0 62 150
084204l 0 0 0 0 1 1 61 148
242711l 0 0 0 0 0 0 69 148
123006l 0 0 0 0 0 0 66 154
060111l 0 0 0 1 0 0 48 151
319507l 1 0 0 1 0 0 75 154
121907l 1 0 0 0 0 1 63 169
132308l 0 0 0 0 0 0 45 137
188710l 1 0 0 0 0 0 85 148
1702/97a 0 0 1 0 0 0 55 155
HOSP NO T_HTNA T_HTNB T_HTNC T_HTND T_STAT T_ASP WEIGHT HEIGHT
024305l 1 0 0 0 1 1 50 145
323399l 1 0 0 0 0 0 85 154
187802l 1 1 0 1 1 1 50 152
365406l 0 0 0 0 0 0 76 147
HOSP NO BMI WAIST C BP_SYS BP_DIAS F HDL F TGL MET SYN MET_SYN*
170094l 25.63 84 140 80 38 132 1 1
310207l 24.03 86 170 70 46 230 1 1
073093l 41.77 106 120 80 9 9 1 1*
209411l 27.01 96 160 90 27 395 1 1
051494l 29.33 92 120 86 36 139 1 1
078907l 31.05 93 110 80 9 9 1 1*
219011l 21.76 72 110 80 49 68 0 0
097512l 33.33 103 110 80 32 194 1 1
327505l 17.43 72 120 80 45 120 0 0
136804l 28.93 85 150 70 40 145 1 1
222603l 31.96 87 170 90 48 217 1 1
338799l 26.84 90 130 80 38 117 1 1
299705l 34.69 109 120 80 36 204 1 1
271101l 32.45 101 130 90 42 134 1 1
068111l 26.61 86 120 80 61 65 0 0
143111l 26.45 87 110 80 9 9 9 9
076411l 27.53 96 140 90 42 133 1 1
318699l 28.94 91 140 80 49 69 1 1
302608l 27.65 91 140 80 49 116 1 1
275649s 28.08 86 120 80 28 139 1 1
197994l 24.68 87 120 80 9 9 1 1*
393201l 24.91 82 120 80 45 73 1 1
268108l 29.33 91 160 90 57 127 1 1
234210l 35.75 103 140 90 9 9 1 1*
340347s 20.37 76 110 80 40 95 0 0
HOSP NO BMI WAIST C BP_SYS BP_DIAS F HDL F TGL MET SYN MET_SYN*
170809l 27.3 85 120 80 66 162 1 1
119108l 25.11 92 110 80 40 158 1 1
072488l 22.97 86 120 70 52 146 1 1
168855s 24.62 92 130 70 9 9 9 9
081511l 29.59 95 110 80 33 141 1 1
123095l 23.65 97 140 70 9 9 9 9
059195l 16.76 52 120 80 75 62 0 0
230100l 23 82 110 70 38 251 1 1
094112l 21.64 82 140 70 9 9 9 9
129908l 22.97 78 110 80 9 9 0 0*
230904l 25.03 95 120 80 43 128 1 1
037703l 33.11 100 130 80 46 361 1 1
110404l 29.78 88 130 80 56 57 1 1
074607l 22.27 76 130 80 33 192 0 0
176125s 17.6 58 120 80 9 9 0 0*
340689s 19.06 69 140 80 56 55 0 0
087904l 21.7 90 160 90 29 317 1 1
097008l 32.05 98 120 80 43 131 1 1
034112l 28.13 82 120 80 37 180 1 1
175207l 23.18 79 120 80 9 9 0 0*
157706l 22.7 81 120 80 49 131 1 1
295201l 28 96 120 80 38 186 1 1
238503l 27.5 98 160 90 9 9 1 1*
055210l 24.3 85 120 80 43 251 1 1
HOSP NO BMI WAIST C BP_SYS BP_DIAS F HDL F TGL MET SYN MET_SYN*
091309l 22.27 75 156 90 41 330 0 0
222974s 26.29 88 130 80 36 132 1 1
9999999 24.79 85 110 80 9 9 1 1*
159689l 26.5 84 120 80 33 208 1 1
083412l 28.51 89 110 80 38 54 1 1
289602l 19.82 76 120 80 30 170 0 0
159705l 31.62 94 120 80 35 180 1 1
313004l 23.08 85 120 80 37 75 1 1
243511l 27.7 90 120 80 34 227 1 1
217008l 30.04 94 110 80 36 182 1 1
080607l 21.21 89 110 80 39 301 1 1
467306l 31.92 100 130 70 47 127 1 1
034912l 29.85 89 120 80 43 144 1 1
050511l 20.37 78 120 80 36 250 0 0
313506l 35.29 88 110 80 43 248 1 1
106911l 20.27 77 110 80 9 9 0 0*
157607l 29.67 93 130 80 55 113 1 1
256004l 31.51 92 110 80 41 287 1 1
142810l 33.2 101 110 80 9 9 9 9
097712l 18.47 77 110 80 9 9 0 0*
125204l 23.63 89 100 80 35 169 1 1
216501l 17.89 77 150 70 53 212 0 0
102104l 23.68 75 130 80 9 9 0 0*
186694l 22.22 79 110 80 50 204 0 0
201689l 27.56 89 110 80 31 272 1 1
HOSP NO BMI WAIST C BP_SYS BP_DIAS F HDL F TGL MET SYN MET_SYN*
045195l 25.3 84 120 80 54 184 1 1
476201l 26.48 87 120 80 69 119 1 1
013003l 36.57 103 110 80 46 142 1 1
209005l 27.82 97 110 80 9 9 1 1*
098697l 29.54 94 110 90 35 167 1 1
329906l 26.22 94 130 80 9 9 9 9
089604l 23.98 86 110 70 57 49 0 0
341799l 21.65 76 110 70 29 78 0 0
155506l 25 87 110 80 32 232 1 1
117205l 25.68 93 120 80 34 99 1 1
068600l 20.95 72 110 80 40 197 0 0
070900l 25.64 92 120 80 42 80 1 1
100412l 27.94 83 110 80 58 98 0 0
422105l 22.58 79 120 70 42 99 0 0
026202l 27.6 93 120 80 9 9 9 9
084204l 27.8 85 110 80 44 222 1 1
242711l 31.5 97 100 80 37 138 1 1
123006l 27.8 81 120 80 36 90 1 1
060111l 21.1 75 140 80 36 146 0 0
319507l 31.6 94 120 80 9 9 1 1*
121907l 22.1 78 110 80 39 113 0 0
132308l 24 73 110 80 9 9 0 0*
188710l 38.8 103 140 80 9 9 1 1*
1702/97a 22.9 81 110 80 9 9 1 1*
HOSP NO BMI WAIST C BP_SYS BP_DIAS F HDL F TGL MET SYN MET_SYN*
024305l 23.8 76 130 80 9 9 0 0*
323399l 35.8 106 120 90 42 119 1 1
187802l 21.6 78 120 80 9 9 0 0*
365406l 35.2 102 140 80 9 9 9 9
MET_SYN*
MET_SYN*
MET_SYN*
MET_SYN*
MET_SYN*
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